ADCT
Adc Therapeutics SA

1,237
Loading...
Loading...
News
all
press releases
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -38.89% and +0.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -22.22% and -1.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -900.00% and +13.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Feb. 3, 2025 LAUSANNE...
PR Newswire·7mo ago
News Placeholder
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference PR Newswire LAUSANNE, Switzerland, Jan. 30...
PR Newswire·7mo ago
News Placeholder
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Jan. 2, 2025 LAUSANNE...
PR Newswire·8mo ago
News Placeholder
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma ADC Therapeutics Announces...
PR Newswire·9mo ago
News Placeholder
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell...
PR Newswire·9mo ago

Latest ADCT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.